Corrections or additions?
These articles were prepared for the
May 2, 2001 edition of U.S. 1 Newspaper. All rights reserved.
On the Move
Junction 08852. Scott E. Coleridge, president & CEO. 732-274-0037;
fax, 732-274-0501. Home page: www.synthoncorp.com
Rawle Hollingsworth, the founder of scientific director of Synthon,
has managed to commercialize a carbohydrate-based chiral technology
platform for the development of a new class of pharmaceuticals that
might help treat auto-immune diseases and cancer. The technology,
which lets researchers inhibit the activity of the enzyme PNP, is
being used in research on a lymphoma treatment now in clinical trials.
The pharmaceutical company conducting these trials has not been
The chirality of a molecule is important to drug development.
used to develop therapeutic drugs typically form in non-chiral, mirror
images of themselves. Each mirror image can react very differently
in the body. For example, one molecule may show a desired therapeutic
effect, but its mirror image may cause significant, undesirable side
Because the FDA requires that the efficacy and safety of each mirror
image must be proved before a drug can be marketed, drug development
companies must go through the costly process of developing batches
of chiral molecules. Synthon has technologies to simplify the process
and decrease the cost. It has shown it can do this in drugs for
reduction, central nervous system disorders (anti-depressants),
muscle relaxants, and anti-virals.
Preparing molecules to deter PNP activity might actually help to
a new drug development platform. Until now, this molecular platform
has stumped researchers, because it has three contiguous chiral
says Scott E. Coleridge, the CEO. "As we are able to decode the
genetic basis for disease," says Coleridge, "chiral chemistry
advances will provide the ability to create the molecules needed to
develop new types of target therapies."
Hollingsworth, a professor at Michigan State University, moved the
company from Michigan to New Jersey to get better access to current
and potential clients. (U.S. 1, May 24, 2000).
Synthon is a fine chemicals and custom synthesis company that can
produce high purity chiral intermediates for the pharmaceutical and
biotechnology industries. An estimated 60 to 70 percent of all drugs
over the next five years will be chiral, and the chiral chemicals
market for pharmaceuticals is expected to exceed $5 billion by 2003.
Princeton 08543-5300. James E. Carnes, president & CEO. 609-734-2000;
fax, 609-734-2040. Home page: www.sarnoff.com
Sarnoff has announced a new miniature camera that could be inexpensive
enough for the wide use in automotive and surveillance applications.
The BLINC digital camera, just one inch square, can be made from the
mass market CMOS chips that also make cell phones — yet it can
transmit high quality video images under poor light conditions. It
will be inexpensive, about the price of a computer mouse, and will
require much less power than its competitors.
Sarnoff is looking for partners to form its own company to manufacture
CMOS imagers — and possibly the miniature cameras.
Suite 206, Princeton 08540. Donald L. Drakeman, president.
fax, 609-430-2850. Home page: www.medarex.com
Neuro Therapeutics has signed on to use Medarex’s HuMAb-Mouse
to develop fully human antibody therapeutics for central nervous
disorders. Both companies will share equally in the preclinical and
clinical development and commercialization of any products that
Privately held, NeuroTherapeutics began at the University of British
Columbia and is located in Vancouver.
08691. Joseph Mo, CEO. 609-208-9688; fax, 609-208-1868. Home page:
NexMed released Phase I clinical trial data on Femprox cream treatment
for female sexual arousal disorder. The study of 64 healthy women
in Miami, from ages 21 to 60, showed that Femprox was safe and well
tolerated at all doses. Femprox is designed to improve vaginal
and increase sexual arousal and pleasure during intercourse. Phase
II proof of concept studies will involve 100 patients at 11 sites.
Michael Starr, CEO. 609-951-0070; fax, 609-951-9330. Home page:
A-1 Limousine has bought Elite Limousine, based in Allentown,
Elite is the largest ground transportation company in the Lehigh
and this will be the third location for A-1. The expansion will add
50 more vehicles for a total of 300 limousines, sedans, vans, and
motor coaches. A-1, which also has a dispatch center in Bound Brook,
will now go to five airports: Newark, LaGuardia, JFK, Philadelphia,
and Lehigh Valley. As a subsidiary, Elite will keep its name,
The company was founded by president and CEO Michael Starr in 1964,
and started at an Arco gas station located on Route 1.
Princeton 08540. Curt Welling, CEO. 609-606-3000; fax, 609-606-3297.
Home page: www.princetonecom.com
New Century Equity Holdings Corp. and Mellon Ventures led $20 million
in convertible debt financing for the provider of electronic billing
and payment services. Other investors were SG Capital Partners (the
merchant banking affiliate of Societe Generale), Bottomline
Terra Lycos Ventures, and BT Investment Partners.
"This is a strong endorsement of Princeton eCom’s business, its
business model, and its prospects by our current investors," says
Curt Welling, Princeton eCom’s CEO. Welling has also announced a deal
to process electronic payments for Pennsylvania-based NCO Group Inc.,
the largest provider of accounts receivable collection services in
08540. David Reim, president. 609-252-9741; fax, 609-252-1425. Home
Catterton Partners has completed a $10 million private equity minority
investment in the healthcare E-business solution firm. "The
is a validation of Simstar’s historic success and our ability to
to redefine the pharmaceutical E-marketing space," says David
Reim, president of Simstar. "Unlike many other companies that
receive outside investment, Simstar has been profitable every year
since inception. We are using these funds to build on our six years
of E-pharma innovation and leadership and capitalize on a large market
Based in Greenwich, Connecticut, Catterton Partners works in the
products and services space and has invested in FloorGraphics (at
Vaughn Drive) and Naviant, among others (www.cpequity.com). Simstar
offers strategy, development, and servicing of E-business solutions
for the pharmaceutical and healthcare industries
Brunswick 08901. Marvin Wurtzelman, president. 732-247-0022; fax,
732-247-4622. Home page: www.tmacinc.com
Marvin Wurtzelman’s technology company has been named regional prime
contractor of the year for the region that includes New Jersey, New
York, Puerto Rico, and the U.S. Virgin Islands. He will receive the
award on Wednesday, May 2, and will enter the national competition.
Wurtzelman’s company designs and manufacturers custom radio frequency
and microwave amplifiers. An alumnus of the SBDC incubator on Jersey
Avenue, it was named by Deloitte & Touche as one of the 500 fastest
growing technology companies in the nation.
Princeton Corporate Center 4th floor, Box 5305, Princeton 08543-5305.
Albert A. Angrisani, president and CEO. 609-520-9100; fax,
Home page: www.totalres.com
A new product from Total Research, Customer Profitability Management,
links customer loyalty and customer profitability by using information
technology and economic analysis. With CPM, market research is planned
so that financial analysts will be able to determine the cost and
profitability of customer relationships. "CPM’s economic analysis
lets senior management know if they do X, then Y will be the
says James M. Salter, senior vice president of Total Research.
Corrections or additions?
This page is published by PrincetonInfo.com
— the web site for U.S. 1 Newspaper in Princeton, New Jersey.